Login or Register to unlock everything MedSchool has to offer!
Monoclonal Antibodies
 
 
 

Anti-CD-20 Antibodies

 
 
  •  
    IV / Subcut
    Rituximab
    Mabthera 

Overview

    • Mechanism of Action

    • A monoclonal antibody that targets CD20, a transmembrane protein on the surface of B cells, resulting in antibody-dependent and complement-dependent cytotoxicity.

Clinical Use

    • Indications

    • Chronic lymphocytic leukaemia (CLL)
    • Non-Hodgkin’s lymphoma (NHL)
    • Rheumatoid arthritis
    • Granulomatosis with polyangiitis (GPA)
    • Microscopic polyangiitis (MPA)
    • Adverse Effects

    • Bone marrow suppression – leucopaenia, anaemia, thrombocytopaenia
    • Injection site reaction
    • Progressive multifocal leukoencephalopathy (PML)
    • Nausea / vomiting
    • Angioedema
Last updated on November 8th, 2018
 
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------
 

Read More...

 Bou-Assaly W, Mukherji S. Cetuximab (erbitux). American Journal of Neuroradiology. 2010 Apr 1;31(4):626-7. Ellis LM. Mechanisms of action of bevacizumab as a component of therapy for metastatic colorectal cancer. InSeminars in oncology 2006 Oct 31 (Vol. 33, pp. S1-S7). WB Saunders. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, Carcereny E. Pembrolizumab for the treatment of non–small-cell lung cancer. New England Journal of Medicine. 2015 May 21;372(21):2018-28. Giles F, Estey E, O'Brien S. Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia. Cancer: Interdisciplinary International Journal of the American Cancer Society. 2003 Nov 15;98(10):2095-104. Ibrahim RA, Berman DM, DePril V, Humphrey RW, Chen T, Messina M, Chin KM, Liu HY, Bielefield M, Hoos A. Ipilimumab safety profile: Summary of findings from completed trials in advanced melanoma. Journal of Clinical Oncology. 2011 May 20;29(15_suppl):8583-. Lee HT, Lee JY, Lim H, Lee SH, Moon YJ, Pyo HJ, Ryu SE, Shin W, Heo YS. Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab. Scientific reports. 2017 Jul 17;7(1):5532. Maloney DG. Mechanism of action of rituximab. Anti-cancer drugs. 2001 Jun;12:S1-4. Mone AP, Cheney C, Banks AL, Tridandapani S, Mehter N, Guster S, Lin T, Eisenbeis CF, Young DC, Byrd JC. Alemtuzumab induces caspase-independent cell death in human chronic lymphocytic leukemia cells through a lipid raft-dependent mechanism. Leukemia. 2006 Feb 1;20(2):272-9. Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Cs?szi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O’Brien M. Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer. New England Journal of Medicine. 2016 Nov 10;375(19):1823-33. Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer.Nature reviews. Cancer. 2012;12:278-287. Tarhini A, Lo E, Minor DR. Releasing the brake on the immune system: ipilimumab in melanoma and other tumors. Cancer biotherapy & radiopharmaceuticals. 2010 Dec 1;25(6):601-13. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, Pegram M, Oh DY, Diéras V, Guardino E, Fang L. Trastuzumab emtansine for HER2-positive advanced breast cancer. New England Journal of Medicine. 2012 Nov 8;367(19):1783-91.
Feedback